The FDA stated that efficacy was not demonstrated for PTC Therapeutics, prompting research notes from RBC Capital.
2 reports, 2 independent
Updated Aug 20
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA stated that efficacy was not demonstrated for PTC Therapeutics, prompting research notes from RBC Capital.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
PTC Therapeutics
pharmaceutical company
Nothing else this week.
Related events
- The Charlotte Lozier Institute found that the FDA lacked sufficient evidence in its review process.
- Arthur Caplan questioned the FDA regarding the status of clinical trials in 2006.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- FDA provided guidance for HCW Biologics' IND application.
- The FDA requested additional clinical data from Unicycive Therapeutics.
Coverage
Newest first; wire copies grouped- TipRanksPTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich’s
- BioPharma DivePTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPha